ABOUT THE PRODUCT
INX-315 is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor in clinical development for the treatment of patients with CDK4/6 inhibitor resistant ER+/HER2- breast cancer or CCNE1-Amplified Solid Tumors.
Information is owner-confirmed
Last updated 1 month ago
Price range